v3.26.3
Balance Sheet Components - Schedule of Components of Balance Sheet (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Sep. 30, 2025
Dec. 31, 2024
Balance Sheet Related Disclosures [Line Items]        
Cash $ 134,595 $ 97,183    
Restricted cash-short term 1,360 1,400    
Restricted cash-noncurrent 252 250    
Total cash and restricted cash 136,207 98,833 $ 66,053 $ 109,631
Accounts receivable [1] 189,584 234,226    
Allowance for doubtful accounts (326) (326)    
Accounts receivable, net 189,258 233,900    
Raw materials 70,436 72,516    
Work in progress 41,363 12,875    
Finished goods 232,839 217,945    
Inventories 344,638 303,336    
Prepaid inventory [2] 39,560 856    
Prepaid expenses 8,743 7,671    
Others 19,336 21,112    
Prepaid expenses and other current assets 67,639 29,639    
Total property and equipment 87,669 80,748    
Less: Accumulated depreciation and amortization (58,764) (49,234)    
Property and equipment, net 28,905 31,514    
Right-of-use assets $ 60,752 $ 57,600    
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets Other assets    
Deferred tax asset $ 13,724 $ 11,371    
Call option to acquire business, at cost [3] 4,810      
Non-marketable equity investment 2,750      
Other 4,482 4,616    
Other assets 86,518 73,587    
Accrued reserves for customer incentive programs 52,453 61,173    
Accrued reciprocal inventory purchases - nonmonetary transactions [4] 40,813 1,040    
Accrued reserves for sales returns 36,429 37,760    
Accrued payroll and related expenses 21,378 26,830    
Operating lease liabilities, current $ 18,006 $ 16,400    
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other liabilities and accrued expenses Other liabilities and accrued expenses    
Accrued freight expenses $ 13,546 $ 16,037    
Sales and use tax and value-added tax payable 4,727 11,087    
Accrued warranty 7,214 8,065    
Contract liabilities 5,977 8,998    
Other 27,211 24,885    
Other liabilities and accrued expenses 227,754 212,275    
Operating lease liabilities, noncurrent $ 53,868 $ 52,785    
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other liabilities, noncurrent Other liabilities, noncurrent    
Other $ 3,647 $ 3,010    
Other liabilities, noncurrent 57,515 55,795    
Manufacturing Equipment        
Balance Sheet Related Disclosures [Line Items]        
Total property and equipment 34,700 30,957    
Leasehold Improvements        
Balance Sheet Related Disclosures [Line Items]        
Total property and equipment 23,074 23,260    
Computer Equipment, Software and Office Equipment        
Balance Sheet Related Disclosures [Line Items]        
Total property and equipment 21,904 19,194    
Furniture and Fixtures        
Balance Sheet Related Disclosures [Line Items]        
Total property and equipment $ 7,991 $ 7,337    
[1] As of September 30, 2026, two customers represented 37.1% and 11.2% of our accounts receivable, net balance, respectively. As of December 31, 2025, two customers represented 42.0% and 14.4% of our accounts receivable, net balance, respectively.
[2] See “Nonmonetary Transactions” below for additional information.
[3] On July 31, 2026, the Company completed a Collaboration and License Agreement (the “License Agreement”) and a related Call Option Agreement (the “Call Option Agreement”) with a privately held software technology company (the “Counterparty”). The arrangement grants the Company an exclusive, worldwide license to integrate the Counterparty’s technology into its products and an exclusive option to acquire 100% of the Counterparty’s outstanding equity.

Under the License Agreement, the Company paid the Counterparty a one-time, non-refundable cash payment of $6.0 million. The payment represents consideration for both the license rights and the call option. The Company allocated the payment between the various elements in the agreement on a relative fair value basis, resulting in $4.8 million allocated to the call option. The Call Option Agreement grants the Company an option to acquire all of the Counterparty’s outstanding equity for a purchase price of $60.0 million in cash, subject to a quality-of-earnings adjustment, with aggregate consideration capped at $72.0 million, adjusted for the $6.0 million payment already paid. Exercise of the option and consummation of any acquisition remain subject to negotiation of definitive acquisition agreements and customary closing conditions, including the Counterparty’s board and stockholder approvals.

The Company’s exclusive right to the option is effectively limited to the period through March 31, 2027, after which it becomes non-exclusive. Absent exercise of the option or termination by the Counterparty, the option expires on September 30, 2027. As of the date these condensed consolidated financial statements were issued, the Company had not exercised the call option.
[4] See “Nonmonetary Transactions” below for additional information.